ReviewNanomedicine (London, England)2025
Strategies to enhance the effects of nanotechnology-mediated photodynamic therapy.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reprogramming Photodynamic Therapy with BODIPY Photosensitizers: From Local Phototoxicity Toward Precision Photodynamic Oncology.Molecules (Basel, Switzerland) · 2026Review
- Nanosystem-Mediated Phototherapy (PDT/PTT) - Chemodynamic Therapy for Synergistic Antitumor Therapy: Strategies and Advances.International journal of nanomedicine · 2026Review
- Overcoming Therapeutic Resistance in Triple-Negative Breast Cancer: Targeting the Undrugged Kinome.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Photodynamic therapy (PDT) is a noninvasive therapeutic approach, particularly effective in tumor treatment. PDT utilizes photosensitizers (PSs) to absorb light at specific wavelengths, converting photon energy into chemical energy and subsequently generating cytotoxic reactive oxygen species (ROS). These ROS trigger cell death through apoptosis, necrosis and autophagy-related pathways. Compared with conventional therapies, PDT exhibits significant advantages, including high selectivity, repeatability, enhanced safety, minimal side effects, low drug resistance, and compatibility with radiotherapy or chemotherapy. However, due to the limited tissue penetration depth of light, PDT demonstrates suboptimal efficacy in treating deep tumors. Additionally, limitations such as poor targeting of photosensitizers and unfavorable factors in the tumor microenvironment greatly restrict PDT's therapeutic efficacy and clinical applicability. To enhance PDT efficacy, various strategies have been explored, among which nanotechnology has emerged as a key research focus. This review summarizes multiple approaches to augmenting nanotechnology-mediated PDT, with emphasis on achieving targeted delivery of photosensitizers (tissue, cell, and organelle-level), improving the performance of photosensitizers and modulating the tumor microenvironment. These insights provide theoretical guidance and practical references for developing novel and efficient PDT nanoplatforms. We conducted the literature search in PubMed, Elsevier ScienceDirect, Web of Science, Wiley and Scopus (from 2004 to 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.